|

Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

RECRUITINGSponsored by Shanghai Zhongshan Hospital
Actively Recruiting
SponsorShanghai Zhongshan Hospital
Started2024-05-15
Est. completion2025-05-20
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06382103

Summary

Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with a first diagnosis of HCC.
* Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy.
* Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level.

Exclusion Criteria:

* Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma.
* Any other concurrent malignancy.
* History of organ transplant or hepatic encephalopathy.

Conditions4

CancerHepatocellular CarcinomaLiver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.